NASDAQ$SKIN
SkinHealth Systems Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported a strong fourth quarter, exceeding expectations and achieving significant year-over-year growth.
BeautyHealth reported a strong Q4 2022, with net sales increasing by 26% year-over-year to $98.1 million and net income reaching $3.8 million. Adjusted EBITDA also saw a substantial increase of 92% to $16.3 million. The company's performance was driven by growth in both delivery systems and consumables, with notable contributions from the Americas and APAC regions.
- Net sales increased by 26% to $98.1 million compared to Q4 2021.
- Delivery Systems net sales increased +19% to $50.7 million.
- Consumables net sales increased +35% to $47.4 million compared to Q4 2021.
- Adjusted EBITDA increased +92% to $16.3 million compared to Q4 2021.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$98.1M
Revenue by segment
Beauty Health · $98.1M total across 2 segments · Q4 2022
- Delivery Systems$50.7M+18.7%51.7%
- Consumables$47.4M+34.7%48.3%
Forward guidance
BeautyHealth expects net sales in the range of $450 to $470 million for fiscal 2023 and reiterates its outlook for fiscal 2023 adjusted EBITDA margin of 18% to 20% and its fiscal 2025 long-range outlook of $600 million to $700 million net sales and 25% to 30% adjusted EBITDA margin.
Tailwinds
- Net sales in the range of $450 to $470 million for fiscal 2023
- Fiscal 2023 adjusted EBITDA margin of 18% to 20%
- Fiscal 2025 long-range outlook of $600 million to $700 million net sales
- Fiscal 2025 adjusted EBITDA margin of 25% to 30%
- Fiscal 2023 gross margin to exceed fiscal 2022 gross margin
Headwinds
- Potential risk for further market closures or other restrictive measures from existing or new COVID-19 strains
- Uneven global rollout and adoption of vaccines
- Inflationary headwinds related to higher raw material, shipping and labor costs
- Assumes no material deterioration in general market conditions or other unforeseen circumstances beyond our control
- Does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account any acquisitions, dispositions or financings during 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro